Vanguard Global Advisers
RNTX

Vanguard Global Advisers’s Rein Therapeutics RNTX Stock Holding History

Vanguard Global Advisers’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.3K Hold
12,774
– – ﹤0.01% 3425
2026
Q1 		$16.6K Buy
+12,774
New +$15.8K ﹤0.01% 3367

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Vanguard Global Advisers's RNTX Position: Q2 2026 in Review

Vanguard Global Advisers held its Rein Therapeutics (RNTX) position steady in Q2 2026 at 12,774 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3425.

Vanguard Global Advisers first reported a position in RNTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $16.6K in Q1 2026. 56 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Vanguard Global Advisers held 12,774 shares of Rein Therapeutics worth $13.3K as of Q2 2026.
  • Vanguard Global Advisers left its Rein Therapeutics share count unchanged in Q2 2026.
  • Rein Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3425 holding.
  • Vanguard Global Advisers first reported a position in Rein Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Rein Therapeutics position peaked at $16.6K in Q1 2026.
  • 56 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.